Decidua Stromal Cell 2.0 clinical trials

A multicenter, open-label, randomized, phase II clinical trial comparing safety and durable overall response rate (DOR) at 56 days in patients with steroid resistant severe acute GvHD after allogeneic hematopoietic stem cell transplantation treated with decidua stromal cells (DSC) or best available treatment (BAT)

This study looks at a new cell treatment for severe GvHD in adults after a stem cell transplant. It compares the new treatment with standard care to see if it's safe and helps improve patient conditions and how long that improvement lasts.